The blood sugar lowering activities of Mounjaro in the body happen in a glucose-dependent way. Meaning only when glucose is high does Mounjaro trigger the body to release more insulin to control it. GLP-1 Receptor Agonist drugs work to lower blood sugar by enhancing insulin secretion, and only enhances insulin secretion in a glucose-dependent manner. If a nondiabetic person is not suffering hyperglycemia, their blood sugar will not be lowered.
“GLP-1 metabolites inhibit hepatic glucose production, exert antioxidant cardio- and neuroprotective actions, reduce oxidative stress in vasculature and have both anti-apoptotic and proliferative effects in pancreatic β-cells, putatively by the modulation of mitochondrial functions. These findings have implications in energy homeostasis, obesity and its associated metabolic and cardiovascular complications as well as incretin-based therapies for the treatment of diabetes and obesity.”
GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products (paywall)
https://pubmed.ncbi.nlm.nih.gov/28040864/
“The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively.”
Tirzepatide Once Weekly for the Treatment of Obesity
July 2022, New England Journal of Medicine
https://www.nejm.org/doi/10.1056/NEJMoa2206038
From ENDO 2021: Ushering in a New Era of Sustainable Weight Loss with Incretin-Based Therapies
https://www.clinicaloptions.com/diabetes/programs/2021/obesityendo2021